Clinical trial NCT00296335: Trial of Adjuvant Chemotherapy for Gastric Cancer
Official title: A Phase III Randomized Controlled Trial of Adjuvant Chemotherapy for Advanced Gastric Adenocarcinoma
Study type: INTERVENTIONAL
Overall status: COMPLETED
Phase: PHASE3
Conditions: Stomach Cancer
Keywords: Stomach cancer
Adjuvant chemotherapy
Mitomycin
Cisplatin
Doxifluridine
Lead sponsor: Asan Medical Center
Sponsor class: OTHER
Collaborators: name: Ulsan University Hospital
name: Hallym University Medical Center
First posted: 2006-02-27
Enrollment: 855
Sex: ALL
Minimum age (years): 18
Maximum age (years): 69
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Allocation: RANDOMIZED
Intervention model: PARALLEL
Primary purpose: TREATMENT

Brief summary: This is a phase III randomized study designed to evaluate the efficacy of mitomycin, doxifluridine, and cisplatin compared to mitomycin and doxifluridine.

Detailed description: Stomach cancer is the most common cancer in Korea and one of the major health problems worldwide. The most effective treatment for gastric cancer is curative surgical resection of primary tumor. However, a substantial number of patients eventually die of recurrences after curative resection. A number of randomized trials investigating the role of adjuvant chemotherapy have been conducted. However, the efficacy of adjuvant chemotherapy is still controversial and varied between Western and Asian trials. Meta-analysis of Western trials didn't demonstrate the benefit of adjuvant chemotherapy after curative resection. Conversely, some Asian studies have demonstrated the efficacy of adjuvant chemotherapy after curative resection. In a previous study, mitomycin plus tegafur prolonged the survival in resected gastric cancer compared to no treatment.

This study is designed to evaluate the efficacy of mitomycin, cisplatin and prolonged treatment with doxifluridine compared to mitomycin plus doxifluridine.

Eligibility criteria: Inclusion Criteria:

* Pathologically proven gastric adenocarcinoma
* Curative resection was done
* stage II, IIIA, IIIB, IV (including T4, lesions or N3, but excluding M1 lymph node metastasis)
* age: 18-69 years old
* Performance status: ECOG 0-2
* Adequate bone marrow function (WBC ≥ 4,000/ul, platelet count ≥ 100,000/ul, hemoglobin ≥ 10 g/dl)
* Adequate renal function (serum creatinine≤ 1.5)
* Adequate liver function (serum bilirubin ≤1.5 mg/dl, AST/ALT ≤ 3 x normal upper limit)
* Written informed consent was signed by the patient

Exclusion Criteria:

* Previous chemotherapy or radiotherapy
* Active ongoing infection which antibiotic treatment is needed
* Pregnant or lactating women
* Psychosis or convulsion disorder
* Ascites in preoperative abdomen CT
* Systemic disease which interfere the administration of chemotherapy
* Previous history of other malignancy except cured non-malignant skin cancer and uterine cervical cancer in situ

Primary outcomes:
measure: Relapse-free Survival Rate
timeFrame: 3 years
Secondary outcomes:
measure: Overall Survival Rate
timeFrame: 3 years
measure: Number of Patients With Adverse Events
timeFrame: Up to 3 years
Other outcomes:
Locations:
city: Seoul
country: Korea, Republic of
facility: Asan Medical Center
Study officials:
affiliation: Asan Medical Center
name: Yoon-Koo Kang, M.D.,Ph.D.
role: PRINCIPAL_INVESTIGATOR
References: